Wilms' Tumor Clinical Trials

A listing of Wilms' Tumor medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 64 clinical trials
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

This phase II Pediatric MATCH trial studies how well palbociclib works in treating patients with Rb positive solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating alterations (mutations) in cell cycle genes that have spread to other places in the body and have come back or do not respond to …

cellular therapy
cns tumors
anti-cancer agents
antineoplastic
platelet count
  • 115 views
  • 25 Sep, 2021
  • 82 locations
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

This phase II Pediatric MATCH trial studies how well samotolisib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with TSC or PI3K/MTOR mutations that have spread to other places in the body (metastatic) and have come back (recurrent) or do not respond to treatment (refractory). Samotolisib …

anti-cancer agents
platelet count
lymphoma
nervous system disorder
cancer treatment
  • 377 views
  • 24 Sep, 2021
  • 86 locations
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

This phase II Pediatric MATCH trial studies how well larotrectinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with NTRK fusions that have spread to other places in the body and have come back or do not respond to treatment. Larotrectinib may stop the growth of …

cellular therapy
cns tumors
nervous system disorders
anti-cancer agents
antineoplastic
  • 352 views
  • 12 Sep, 2021
  • 84 locations
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

This phase II Pediatric MATCH trial studies how well olaparib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with defects in deoxyribonucleic acid (DNA) damage repair genes that have spread to other places in the body (advanced) and have come back (relapsed) or do not respond …

anti-cancer agents
platelet count
lymphoma
cancer treatment
cns involvement
  • 199 views
  • 22 Aug, 2021
  • 75 locations
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have spread to other places in the body and have come back or do not respond to treatment with FGFR mutations. Erdafitinib may stop the growth of …

anti-cancer agents
platelet count
lymphoma
cancer treatment
cns involvement
  • 261 views
  • 22 Aug, 2021
  • 82 locations
Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

This phase II Pediatric MATCH trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back (recurrent) or do not respond to treatment (refractory) and have spread to other places in the body (advanced). …

cellular therapy
cns tumors
anti-cancer agents
antineoplastic
ROS1
  • 68 views
  • 23 Sep, 2021
  • 78 locations
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away). The trial will test 2 combinations of therapy and participants will be …

  • 0 views
  • 03 Jul, 2021
  • 2 locations
Multi-antigen T Cell Infusion Against Neuro-oncologic Disease

high-risk CNS tumors known to typically have positivity for one or more Tumor Antigen Associated (TAA) (WT1, PRAME and/or Survivin) will be eligible. TAA-T will all be generated from patient peripheral

cancer
cns neoplasm
medulloblastoma
malignant glioma
ependymoma
  • 4 views
  • 02 Aug, 2021
  • 1 location
Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)

that will train them to recognize the tumor proteins WT1, NY-ESO-1, PRAME, and Survivin, which are expressed on most AML and MDS cancer cells. The cells will be infused at least 30 days post-allogeneic

hodgkin's disease
cancer
leukemia
aml/mds
chromosome abnormality
  • 54 views
  • 30 Jun, 2021
  • 2 locations
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

To evaluate the safety and tolerability of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers. Patients will be followed long-term for Overall Survival (OS) and safety. The study will enroll approximately 90 patients and maximum study treatment duration is approximately 2.13 years.

estrogen
bevacizumab
progesterone receptor
azacitidine
niraparib
  • 130 views
  • 27 Mar, 2021
  • 19 locations